Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure

investors.com/news/technology/summit-therapeutics-stock-pd-1-vegf-bispecific-fails

Summit Therapeutics stock plunged Friday after its highly watched cancer drug failed to significantly improve overall survival.
The post Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-05-30 13:22:19.
The Entire Business World on a Single Page. Free to Use →